BioWorld MedTech

March 27, 2013

AdreView approved for risk evaluation in HF patients

GE Healthcare (Princeton, New Jersey) reported FDA approval of a new indication for AdreView (Iobenguane I 123 Injection), a molecular imaging agent, to link nerve function in the heart to a patient's mortality risk. Read More

Johns Hopkins students develop simple, effective cooling device

Report from Europe: Miracor treats German patient with PICSO

Washington roundup: McConnell to House; vote on stand-alone device tax repeal

Agreements/contracts: PrimeraDx to co-develop diagnostics with Quest

Deals roundup: ICCNexergy in plan to acquire Applied Power

HIT roundup: TGen tests secure connection using Obsidian's Longbow tech

Financings roundup: Medgenics reports exercise of over-allotment option

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 9, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...